ConductScience.org, home

Comparison · NCT03640949-9cbd74cd

Vasopressin and Methylprednisolone vs Placebo: Number of Participants With a Favorable Neurological Outcome at 30 Days

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Vasopressin and Methylprednisolone vs Placebo: Number of Participants With a Favorable Neurological Outcome at 30 Days. Trial comparisons, record NCT03640949-9cbd74cd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03640949-9cbd74cd

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.07590.04860.117wilson
Risk in group 20.07580.04960.114wilson
Risk difference, group 1 minus group 20.000192-0.04690.0488newcombe hybrid score
Risk ratio, group 1 over group 210.5441.85log
Odds ratio, group 1 over group 210.5171.94log
Number needed to treat, for one more participant with the outcome on Vasopressin and Methylprednisolone than on Placebo5,210from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Vasopressin and Methylprednisolone
The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).~Vasopressin, Arginine: 20 IE of vasopressin per dose for a maximum of four doses (80 IU)~Methylprednisolone: 40 mg methylprednisolone once
18237OG000
Group 2Placebo
The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.~NaCl: Placebo
20264OG001

Outcome

Type
SECONDARY
Title
Number of Participants With a Favorable Neurological Outcome at 30 Days
Description
A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.
Time frame
At 30 days
Population

Source ClinicalTrials.gov

Trial

Title
Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
NCT number
NCT03640949
Phases
PHASE2, PHASE3
Conditions
Heart Arrest
Interventions
Vasopressin, Arginine, Methylprednisolone, NaCl
Lead sponsor
Lars Wiuff Andersen
Results first posted
2022-01-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03640949-9cbd74cd